Health

RAS-targeting therapies reshaping pancreatic cancer outlook with significant tumor shrinkage in early trials

The core of this progress lies in the inhibition of RAS gene mutations, which drive the growth of most pancreatic tumors. Until recently, these mutations were considered difficult to target pharmacologically. New oral agents, including daraxonrasib (also known as Rasonk) and ERAS-0015, have shown promising results in initial trials, moving the field from managing symptoms to actively shrinking or eliminating tumors in a subset of patients.

Clinical Evidence and Response Rates

One of the most significant data sets comes from a Phase I/II trial involving 61 participants with recently diagnosed, metastatic pancreatic cancer. In this study, patients received daraxonrasib in combination with standard chemotherapy (gemcitabine and nab-paclitaxel). The results, which followed patients for an average of 18.3 months, indicated that 90.2 percent of patients experienced disease control, meaning their tumors either shrank or stopped growing. Specifically, 60.7 percent of patients achieved an objective response, where tumors shrank beyond a predefined threshold. Notably, in approximately 8 percent of cases—about one in 12 patients—tumors became undetectable on CT scans.

Dr. Wungki Park of the Memorial Sloan Kettering Cancer Center, who is involved in the trial, described the results as “extremely encouraging,” noting a near-doubling in the duration of disease control compared to historical benchmarks. While previous treatments typically yielded progression-free survival of 5 to 7 months, this trial reported a median progression-free survival of 12.8 months. However, direct comparisons are complex due to differences in patient populations and trial conditions.

Photo by National Institute of Allergy and Infectious Diseases on Unsplash

Parallel research supports these trends. Results from the AURORAS-1 Phase I trial, presented at the 38th EORTC-NCI-AACR Symposium, focused on ERAS-0015, a “pan-RAS molecular glue” that binds to active RAS proteins to block growth signals. In a cohort of 83 patients with RAS-mutant pancreatic cancer who had previously undergone other treatments, ERAS-0015 achieved a 44 percent response rate. The drug was generally well-tolerated, with few severe side effects reported. Dr. Judy Wang of Florida Cancer Specialists and Research Institute noted that these response rates represent clinically meaningful activity in a patient group with historically few therapeutic options.

Regulatory Status and Detection Innovations

The momentum in treatment is being matched by regulatory progress. The U.S. Food and Drug Administration (FDA) approved daraxonrasib in August for metastatic pancreatic cancer patients who had previously received anti-cancer treatment. Subsequently, on November 16, the European Union approved the drug for patients who had undergone at least one round of prior therapy. These approvals currently apply to later-line treatments rather than as a first-line standard of care, though the trial data cited above specifically examined its use in patients who had not yet received anti-cancer treatment.

Advancements in detection are also critical to improving survival. Dr. Mark Truty of the Mayo Clinic highlighted the challenge of late diagnosis, noting that common symptoms like abdominal pain or weight loss are non-specific. To address this, Mayo Clinic has initiated a clinical trial using artificial intelligence to analyze CT scans for high-risk individuals. The AI technology can identify subtle tumors that may have been missed by standard radiological review, potentially allowing for earlier intervention when surgical or medical options are more effective.

Photo by Ivan S on Pexels

Uncertainties and Limitations

Despite the optimism, medical experts urge caution. Daraxonrasib and similar agents are not cures. It remains unclear how long the disease remains in remission after the initial response, and whether the observed shrinkage translates into a significant increase in overall survival. The current trials are relatively small and short-term; longer studies are necessary to determine durability and long-term safety.

Furthermore, while the drugs target RAS mutations common in pancreatic cancer, they are also being evaluated in other RAS-mutant solid tumors, including non-small cell lung cancer and colorectal cancer. In the lung cancer cohort of the AURORAS-1 trial, the response rate was even higher at 60 percent, suggesting broader applicability. Nevertheless, the primary focus for pancreatic cancer remains on extending the time patients live with the disease rather than eliminating it entirely.

As World Pancreatic Cancer Day highlights the urgent need for better outcomes, the integration of RAS-targeting therapies and AI-driven screening represents a pivotal shift. The next critical step for the medical community is confirming whether these short-term improvements in tumor control will lead to sustained life extension for the broader patient population.

Brian Kelly

Brian Kelly writes about health, medicine, healthcare systems, and public-health developments. He follows new research, treatment developments, health policy, and major disease-related stories while paying close attention to the quality and limitations of available evidence. Brian's reporting aims to provide clear information and useful context without turning preliminary research or isolated findings into definitive conclusions.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button